Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guadecitabine + ipilimumab + nivolumab
- Development stage
- Unknown
- Lead developer
- Italian Network for Tumor Biotherapy Foundation
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
A combination therapy consisting of guadecitabine (a hypomethylating agent), ipilimumab (an anti-CTLA-4 monoclonal antibody), and nivolumab (an anti-PD-1 monoclonal antibody). This triple combination is designed to enhance anti-tumor immune responses through complementary mechanisms: guadecitabine promotes DNA demethylation and activates innate immunity pathways, while ipilimumab and nivolumab block different immune checkpoints to promote T-cell function and tumor killing. The combination is being investigated primarily for patients with melanoma and non-small cell lung cancer who have developed resistance to prior anti-PD-1/PD-L1 therapy.
- Brand names
- YervoyOpdivo
- Other names
- ipi-nivo-guadecitabine
02
Targets
DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNMT1 (DNA (cytosine-5)-methyltransferase 1)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on guadecitabine + ipilimumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on guadecitabine + ipilimumab + nivolumab.